Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Medical Device

Boston Scientific Subsidiaries Barred From Selling Multiple Drug-Eluting Stent Lines In Germany

This article was originally published in The Gray Sheet

  • News

Executive Summary

A German court had previously blocked Boston Scientific’s German subsidiary from selling drug-eluting stents affected by OrbusNeich’s patent suit; the new injunction closes a loophole, preventing any Boston Scientific subsidiary from selling the devices in Germany.

You may also be interested in...



News In Brief

Maquet acquires LAAx. OrbusNeich says it called the cops on Boston Scientific. More news

News In Brief

Two deputy commissioners depart FDA. NICE takes over U.K. program to encourage adoption of new medical technologies. More news.

Sandoz Prepares For European Natalizumab Launch As Approval Arrives

As it announced the formal European Commission approval of its partnered Polpharma Biologics-developed Tyruko natalizumab biosimilar to Tysabri, Sandoz offered Generics Bulletin a timeframe for its expected launch in Europe.

Table

View full table

Topics

Related Companies

Tags:
Medical Device
Latest Headlines

Minute Insight: Virtual Incision Draws In Another $30m With Its Table-Top Surgical Robot

Generating And Assessing Evidence To Optimize MDR And IVDR Governance and Innovation

Intarcia’s Implantable GLP-1 Gets Unanimous No Vote But Lots Of New Trial Design Advice

Class I Recall For Medline’s Saline Solution Packs

See All
UsernamePublicRestriction

Register

MT032067

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By